Stem Cell Therapy Market Size, Share & Growth Trend Analysis Report (2026 - 2035)

Market Size

The stem cell therapy market, valued at USD 204 million in 2025, is projected to reach USD 321 million in 2026 and USD 1,290 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

• Based on the source of stem cell, allogeneic therapies account for close to 65% of the overall stem cell therapy market share, driven by their off-the-shelf availability and scalability.

• In terms of origin of stem cells, adult stem cells capture close to 80% of the market owing to their established safety and extensive clinical adoption.
• Amongst different types of stem cell, hematopoietic stem cells contribute significantly to the overall market owing to their widespread use in blood disorders, hematological malignancies, and transplantation procedures.
• Based on the lineage of stem cell, bone marrow derived stem cells account for the largest share of the market due to their extensive clinical validation and broad therapeutic applicability.
• In terms of the route of administration, intravenous delivery captures the majority share of the market owing to its ability to support systemic distribution across various stem cell therapies.
• With respect to the therapeutic area, musculoskeletal disorders account for the largest share of the market due to the growing adoption of regenerative therapies for cartilage, bone, and tissue repair.
• Based on end users, hospitals dominate the overall market as they possess the specialized infrastructure and expertise required to administer advanced stem cell therapies.
• Across key geographical regions, North America captures the largest market share owing to substantial research funding, a favorable regulatory environment, and the presence of leading therapy developers.

Market Overview

Stem cell therapy represents a transformative approach in regenerative medicine that utilizes stem cells to repair, replace, or regenerate damaged tissues and restore normal biological function. Owing to their ability to self-renew and differentiate into specialized cell types, stem cells have demonstrated therapeutic potential across hematological, neurological, cardiovascular, musculoskeletal, and autoimmune disorders.

Rising prevalence of chronic and degenerative diseases has intensified demand for therapies capable of addressing underlying disease mechanisms. In response, researchers, healthcare providers, investors, and biotechnology companies are increasing investments in regenerative medicine, expanding clinical research activity, and advancing cell manufacturing technologies. The industry is also witnessing growing interest in induced pluripotent stem cell (iPSC)-based therapies, which offer a scalable source of specialized cells. For instance, in March 2025, Japan approved the world's first treatment developed using reprogrammed human cells, highlighting the clinical potential of iPSC-based therapies.

Despite this progress, the industry continues to face challenges related to high treatment costs, complex manufacturing processes, scalability constraints, and evolving regulatory requirements. Ensuring consistent product quality, maintaining cell viability throughout the stem cell manufacturing process, and establishing large-scale production capabilities remain critical hurdles for developers. Despite these challenges, ongoing technological advancements, expanding clinical evidence, and increasing commercialization efforts are likely to create significant opportunities in the stem cell therapy market.

Recent Developments

• In April 2026, Beam Therapeutics reported Phase 1/2 BEACON trial data for its stem cell-based gene-edited therapy risto-cel in 31 sickle cell disease patients. Results showed durable engraftment, elimination of severe vaso-occlusive crises, and reduced hospitalizations, supporting plans for a Biologics License Application submission expected by the end of 2026.
• In February 2026, Senti Biosciences completed enrollment in a Phase 1 clinical trial of SENTI-202, a logic-gated CAR-NK cell therapy incorporating stem-cell-derived approaches, for relapsed or refractory acute myeloid leukemia. The therapy showed durable complete remissions and favorable safety, and received RMAT designation, supporting accelerated regulatory discussions with the FDA in 2026.
• In January 2026, StemCyte announced that the FDA approved an Expanded Access Program for its RegeneCyte® cord blood–derived stem cell therapy for Long COVID.

Stem Cell Therapy Market Trends

• Partnerships and Collaborations: The market is witnessing an increasing number of strategic partnerships aimed at accelerating clinical development, scaling manufacturing capabilities, and advancing next-generation therapies. For instance, in April 2026, Healios partnered with Minaris Advanced Therapies for commercial manufacturing of cell therapies targeting acute respiratory distress syndrome. Similarly, in January 2026, Cellares collaborated with Stanford Medicine to advance automated manufacturing of gene-edited hematopoietic stem cell therapies.
• Funding and Investments: Over the last five years, public and private investors have allocated substantial capital toward regenerative medicine and stem cell-based therapeutics. This funding activity, along with supportive government initiatives, is helping companies advance clinical programs and commercialization efforts. For instance, in June 2026, Cellares expanded its Series D financing round to USD 327 million through an additional USD 50 million investment to accelerate the buildout of its global cell therapy manufacturing network. Earlier in March 2025, the Government of Canada invested USD 49.9 million in STEMCELL Technologies to expand biomanufacturing capabilities.
• Advancements in Stem Cell Manufacturing Technologies: Companies are investing in automated manufacturing systems, closed processing technologies, and advanced cell expansion platforms to improve product consistency and reduce production costs. For example, in April 2025, Cellares' Cell Shuttle, a fully automated, closed cell therapy manufacturing platform, received the FDA's Advanced Manufacturing Technology (AMT) designation, highlighting the growing industry focus on scalable and standardized manufacturing solutions. Such technological advancements are likely to enhance commercial scalability and support broader adoption of stem cell therapies.
• Growing Focus on Allogeneic Cell Therapies: Industry stakeholders are increasingly prioritizing the development of allogeneic stem cell therapies owing to their scalability, off-the-shelf availability, and ability to serve larger patient populations. As developers seek to overcome manufacturing and logistical limitations associated with patient-specific therapies, investment in allogeneic platforms continues to increase.

Industry Experts on Stem Cell Therapy Market

The stem cell therapy market is likely to benefit from a more supportive regulatory environment and increasing clinical validation of cell-based therapeutics. Highlighting this trend, Lance Alstodt (Chief Executive Officer, BioRestorative Therapies) stated, “We are seeing a convergence of scientific, regulatory, and manufacturing advances that are enabling regenerative therapies to move from experimental concepts toward viable clinical solutions. Regulators are gaining greater familiarity with cell therapies, and clinical trial designs are becoming more rigorous and standardized.”

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Founder and Chief Executive Officer, Small Organization, US
• Founder and Chief Executive Officer, Small Organization, Canada
• Director and Chairman, Department of Cardiac Surgery, Large Organization, Germany
• Director and Chief Operating Officer, Small Organization, Japan
• Director of Business Development, Small Organization, US
• Scientific & Medical Director, Very Large Organization, US
• Co-Founder and Chief Scientist; Former Director, Business Development, Small Organization, Switzerland
• Former President, Small Organization, France
• Former Department Leader, Cell Therapy Innovation and Development, Mid-sized Organization, France

In addition, the market report includes transcripts of the following other third-party discussions:

• President and Chief Executive Officer, Small Organization, US
• Chief Executive Officer and Co-founder, Mid-sized Organization, US
• Chief Executive Officer and Co-founder, Mid-sized Organization, US
• President and Co-founder, Small Organization, US
• Chief Executive Officer, Mid-sized Organization, Japan
• Chief Executive Officer, Small Organization, US
• Founder and Chief Technology Officer, Mid-sized Organization, Belgium
• Vice President of Cell Technology, Mid-sized Organization, Belgium
• Associate Director, Regulatory Affairs, Mid-sized Organization, US
• Team Leader, Research and Development, Mid-sized Organization, Germany

Market Drivers

• Rising Prevalence of Degenerative Diseases: The growing burden of chronic degenerative conditions, including musculoskeletal disorders, cardiovascular disorders, neurological disorders, autoimmune diseases, and cancer, continues to drive demand for stem cell therapies. Unlike conventional treatments that primarily manage symptoms, stem cell-based therapies offer the potential to repair or regenerate damaged tissues, making them a suitable treatment option for complex and progressive diseases.
• Advancements in Regenerative Medicine and Cell Engineering: Continuous progress in stem cell biology, cell expansion technologies, genome editing, and tissue engineering are expanding the therapeutic potential of stem cell therapies. These innovations are improving treatment efficacy, enhancing cell functionality, and enabling developers to explore new applications across a broader range of disease indications.
• Growing Clinical Evidence and Regulatory Approvals: Increasing clinical research activity and a growing number of regulatory approvals are strengthening confidence in stem cell-based therapies. In December 2025, the FDA approved Waskyra™, the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening inherited immune disorder. The therapy utilizes a patient’s own genetically modified hematopoietic stem cells to restore immune function, marking an important regulatory milestone for stem cell-based gene therapies.

Market Segmentation Analysis

Allogeneic Therapies Lead the Stem Cell Therapy Market

Based on the source of stem cells, the global market is segmented into allogeneic therapies and autologous therapies.

According to our market analysis, allogeneic therapies account for close to 65% of the stem cell therapy market share. Their dominance stems from their ability to support scalable and commercially viable treatment models. Unlike autologous therapies, which require patient-specific cell collection and manufacturing, allogeneic therapies enable developers to produce standardized cell products from a single donor and treat multiple patients. This approach improves manufacturing efficiency, streamlines the supply chain, and allows healthcare providers to access readily available therapies. As a result, several developers continue to prioritize allogeneic platforms as they seek to expand access to stem cell therapies across larger patient populations.

It is worth highlighting that autologous therapies are expected to grow at a faster rate during the forecast period till 2035. This growth is driven by the increasing emphasis on personalized regenerative medicine and the ability of autologous therapies to utilize a patient's own cells. Further, advances in cell processing and manufacturing technologies are enabling developers to overcome operational challenges associated with patient-specific therapies, encouraging greater investment in autologous treatment approaches across various therapeutic areas.

Adult Stem Cells Continue to Dominate Clinical Applications

Based on the origin of stem cells, the global stem cell therapy market is segmented into adult stem cells and embryonic stem cells.

Adult stem cells currently capture close to 80% of the overall market. This leadership is driven by their established safety profile, extensive clinical evidence, and broader physician acceptance across multiple therapeutic applications. In addition, adult stem cells avoid many ethical and regulatory concerns associated with embryonic stem cell research, enabling developers to advance clinical programs with fewer societal and regulatory challenges.

Meanwhile, embryonic stem cells are expected to grow faster than adult stem cells during the forecast period till 2035. This growth is supported by advances in cell differentiation technologies, which enable researchers to generate highly specialized cell types for regenerative medicine applications. For instance, in April 2026, BlueRock Therapeutics reported positive Phase I data for bemdaneprocel, a Parkinson's disease therapy composed of human embryonic stem cell-derived dopaminergic neuron progenitor cells, highlighting the growing clinical potential of embryonic stem cell-based platforms.

Hematopoietic Stem Cells Anchor the Stem Cell Therapy Market

Based on the type of stem cells, the market is segmented into hematopoietic stem cells, mesenchymal stem cells, progenitor cells, and other stem cell types.

Hematopoietic stem cells currently account for the largest share of the stem cell therapy market. Their dominance is driven by widespread clinical adoption, well-established transplantation protocols, and extensive clinical evidence. This is further reflected by the approval and commercialization of hematopoietic stem cell-based products such as Omisirge® (Gamida Cell). In addition, standardized collection and processing procedures, established reimbursement pathways, and strong physician familiarity support their broader integration into treatment workflows.

In contrast, mesenchymal stem cells are expected to grow at the highest rate during the forecast period till 2035. This growth is supported by their immunomodulatory and regenerative properties, which allow developers to explore clinical applications across diseases involving inflammation, tissue damage, or impaired healing. Their ability to be sourced from multiple tissues and manufactured in controlled environments also supports their use in next-generation regenerative therapies.

Musculoskeletal Disorders Drive Demand in the Stem Cell Therapy Market

On the basis of therapeutic area, the global market is segmented into autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others.

Currently, musculoskeletal disorders account for the largest share of the stem cell therapy market. This leadership is driven by strong clinical and commercial activity across indications such as osteoarthritis, cartilage defects, bone injuries, and degenerative joint conditions. Stem cell therapies for musculoskeletal disorders primarily target localized tissue repair, making treatment responses easier to assess in clinical settings. In addition, the large patient population affected by age-related joint degeneration continues to create substantial demand for regenerative treatment options.

Conversely, neurological disorders are expected to witness the highest growth during the forecast period till 2035. This growth is driven by increasing research focused on conditions involving irreversible neuronal damage and limited treatment alternatives. Stem cell therapies offer the potential to support neuroprotection, neural regeneration, and functional recovery, creating new opportunities to manage conditions such as Parkinson's disease, Alzheimer's disease, spinal cord injuries, and stroke-related complications.

Market Regional Insights

In terms of key geographical regions, the global stem cell therapy market is distributed across North America, Europe, Asia-Pacific, and Rest of the World.

North America Dominates the Stem Cell Therapies Industry

According to our analysis, North America captures the largest share of the stem cell therapy market. This dominance is supported by a developed regenerative medicine ecosystem, strong academic research capabilities, advanced healthcare infrastructure, and significant public and private investment in cell therapy development. The presence of leading biotechnology companies, such as BlueRock Therapeutics and Gamida Cell, along with specialized treatment centers and established clinical research networks, continues to strengthen the region's position in the global market.

Asia-Pacific: An Emerging Growth Spot of the Stem Cell Therapy Market

This growth is driven by increasing biotechnology investments, expanding cell therapy manufacturing capabilities, and government support for regenerative medicine across China, Japan, South Korea, and India. Regulatory initiatives, including Japan's conditional approval framework for regenerative therapies and South Korea's Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act, have also created a favorable environment for clinical development and commercialization. As regional stakeholders expand research and manufacturing efforts, Asia-Pacific is expected to play an increasingly important role in the stem cell therapy market.

Stem Cell Therapy Market: Scope of the Report

Market Segments

Based on the research, we have segmented the stem cell therapy market into source of stem cell, origin of stem cell, type of stem cell, lineage of stem cell, route of administration, therapeutic area, end users and key geographical regions.

By Source of Stem Cell

• Allogeneic Therapies
• Autologous Therapies

By Origin of Stem Cell

• Adult Stem Cells
• Embryonic Stem Cells

By Type of Stem Cell

• Hematopoietic Stem Cells
• Mesenchymal Stem Cells
• Progenitor Cells
• Others

By Lineage of Stem Cell

• Bone Marrow-Derived Stem Cells
• Adipose Tissue-Derived Stem Cells
• Cord Blood-Derived Stem Cells

By Route of Administration

• Intraarticular Therapies
• Intracoronary Therapies
• Intramuscular Therapies
• Intramyocardial Therapies
• Intrathecal Therapies
• Intravenous Therapies
• Surgical Implants
• Others

By Therapeutic Area

• Autoimmune / Inflammatory Disorders
• Cardiovascular Disorders
• Metabolic Disorders
• Musculoskeletal Disorders
• Oncological Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Others

By End Users

• Ambulatory Surgery Centers
• Hospitals
• Specialty Clinics

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Frequently Asked Questions

Question 1: What is stem cell therapy?

Answer: Stem cell therapy involves the repair of diseased, injured or dysfunctional tissue with the use of stem cells or their derivatives.

Question 2: How big is the stem cell therapy market?

Answer: The current global market size for the stem cell therapy industry is valued at USD 321 million and is projected to reach USD 1,290 million by 2035.

Question 3: What is the CAGR of stem cell therapy market?

Answer: The market is set to grow at a CAGR of 16.7% over the forecast period.

Question 4: How many stem cell therapies have been approved to date, developed by players engaged in the stem cell therapy market?

Answer: 27 stem cell therapies have been approved, till date; popular examples include EYE-01M (developed by Japan Tissue Engineering for the treatment of limbal stem cell deficiency), Stempeucel® (developed by Stempeutics Research for the treatment of critical limb ischemia and knee osteoarthritis) and Strimvelis® (developed by GlaxoSmithKline for the treatment of ADA-SCID).

Question 5: Which key geographical segment is likely to capture majority share in the stem cell therapy market by 2035?

Answer: North America is likely to capture the majority of the market share in the next decade.

Question 6: Which are the top companies in the market for stem cell therapies?

Answer: The top leading companies in the stem cell therapy market include Anterogen, CHA Biotech, Cytopeutics, Hope Biosciences, Mesoblast, Pluri, Takeda and TICEBA.

Question 7: What are the factors driving the stem cell therapy market?

Answer: Rising prevalence of degenerative diseases, advancements in regenerative medicine and cell engineering, along with growing demand for personalized medicine drive the market.